Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METRO I.V. vs METRETON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metronidazole is a nitroimidazole antibiotic that exerts its bactericidal effect by entering bacterial cells and undergoing reduction by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It is selectively toxic to anaerobic bacteria and protozoa.
Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.
Treatment of intra-abdominal infections (e.g., peritonitis, abscess),Treatment of pelvic inflammatory disease,Treatment of bacterial vaginosis,Treatment of trichomoniasis,Treatment of amebiasis (intestinal and extraintestinal),Treatment of anaerobic infections (e.g., bone and joint, central nervous system, respiratory tract, skin and soft tissue),Perioperative prophylaxis (colorectal surgery),Off-label: Helicobacter pylori eradication (with other agents), rosacea (topical), Crohn's disease (perianal fistulas)
Seasonal allergic conjunctivitis,Perennial allergic conjunctivitis,Other allergic ocular conditions
15-30 mg/kg IV loading dose, then 7.5-15 mg/kg IV every 6 hours. Typical adult dose: 500 mg IV every 6-8 hours.
1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.
8 hours (range 6-10 hours) in adults; prolonged to 12-24 hours in hepatic impairment.
Terminal elimination half-life is 24-36 hours; increased in renal impairment (up to 60 hours in anuria)
Metronidazole is extensively metabolized in the liver via oxidation and glucuronidation. The major metabolic pathways involve hydroxylation and side-chain oxidation, mediated by CYP450 enzymes (CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4). The primary metabolites are 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole and 2-methyl-5-nitroimidazole-1-acetic acid, which have minimal antimicrobial activity.
Not extensively metabolized; primarily excreted unchanged in urine.
Renal: 60-80% unchanged; fecal: 6-15% (includes metabolites); biliary: minor contribution.
Renal (80-90% as unchanged drug and metabolites), biliary/fecal (10-20%)
<20%, primarily to albumin.
75-85% bound to albumin and alpha-1-acid glycoprotein
0.6-0.7 L/kg; indicates extensive distribution into tissues including CSF and abscess cavities.
0.5-1.0 L/kg; indicates moderate tissue distribution
Oral: 80-90%; IV: 100%.
Oral: 50-70% (first-pass metabolism); Intramuscular: 80-100%
Cr Cl > 50 m L/min: no adjustment; Cr Cl 10-50 m L/min: increase dosing interval to every 12 hours; Cr Cl < 10 m L/min: increase interval to every 24 hours.
Cr Cl 10-50 m L/min: administer every 12 hours; Cr Cl <10 m L/min: administer every 12-18 hours or consider dose reduction by 50%.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75%.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce dose by 75%.
Loading dose: 15-30 mg/kg IV; maintenance: 7.5 mg/kg IV every 6 hours. For neonates < 7 days: 15 mg/kg IV every 24 hours; 7-28 days: 15 mg/kg IV every 12 hours.
0.5-1 mg/kg intramuscularly or intravenously every 6-8 hours; maximum 25 mg per dose for children <40 kg.
Use with caution; adjust dose based on renal function (Cr Cl) and monitor for neurotoxicity. Start at lower end of dosing range.
Start at lower end of dosing range (e.g., 0.5-1 mg/kg) with extended intervals (every 8-12 hours) due to decreased renal function and increased sensitivity.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. It should be used only for approved indications and for the shortest duration necessary.
None
Carcinogenicity: Avoid unnecessary use,Peripheral neuropathy: Risk with high doses or prolonged treatment; discontinue if signs occur,Central nervous system effects: Encephalopathy, convulsions, aseptic meningitis; discontinue if symptoms develop,Hepatotoxicity: Risk of severe hepatic injury, including acute liver failure; monitor liver function,Blood dyscrasias: Leukopenia, neutropenia; caution in patients with history of blood disorders,Interaction with alcohol: Disulfiram-like reaction (nausea, vomiting, flushing); avoid alcohol during therapy and for at least 3 days after,Cochrane interaction: Increased INR with warfarin; monitor INR,Renal impairment: Accumulation of metabolites; dosage adjustment may be needed,Prolonged therapy: Monitor for superinfection and neurological symptoms
Do not inject; for ophthalmic use only.,May cause transient burning or stinging.,Use with caution in patients with narrow-angle glaucoma.
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (unless alternative treatments not available),Breastfeeding (withhold nursing for 12-24 hours after dose),Concurrent use of disulfiram (psychotic reactions may occur),Severe hepatic impairment (metronidazole is hepatically cleared)
Hypersensitivity to any component of the formulation
No significant food interactions. However, alcohol is strictly contraindicated. Use alcohol-free formulations of medications and avoid alcoholic beverages.
Avoid excessive alcohol intake (increases risk of lactic acidosis). No specific food restrictions, but consistent carbohydrate intake is recommended to prevent hypoglycemia. Grapefruit may increase metformin levels (use caution).
Pregnancy category B. No evidence of teratogenicity in human studies; crosses placenta. Avoid during first trimester unless benefit outweighs risk; use only if clearly needed.
Pregnancy Category C: Fetal risk cannot be ruled out. First trimester: Increased risk of cleft palate and cardiac malformations due to corticosteroid component (prednisolone). Second and third trimesters: Potential for intrauterine growth restriction, adrenal suppression in neonate. Avoid use unless benefit outweighs risk.
Excreted in breast milk in low concentrations; M/P ratio approximately 1.0. Considered compatible with breastfeeding; monitor infant for diarrhea or candidiasis.
Prednisolone and chlorpheniramine (components of METRETON) are excreted into breast milk. M/P ratio for prednisolone is approximately 0.5-0.7. Low risk at maternal doses <20 mg/day; higher doses may cause infant adrenal suppression or growth delay. Consider alternative antihistamine with lower excretion.
No specific dose adjustment required in pregnancy; pharmacokinetics not significantly altered. Use standard dosing based on infection severity and renal function.
No specific dose adjustment required; use lowest effective dose for shortest duration. Pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism) may reduce efficacy of standard doses; monitor clinical response and consider dose titration. Avoid high-dose or prolonged therapy.
METRO I. V. (metronidazole) is a nitroimidazole antibiotic effective against anaerobic bacteria and protozoa. It has excellent bioavailability following intravenous administration. Monitor for peripheral neuropathy with prolonged use. Avoid alcohol during therapy and for 48 hours after last dose due to disulfiram-like reaction. Dose adjustment required in severe hepatic impairment (Child-Pugh C). May cause metallic taste, which is benign. Use with caution in patients with CNS disorders due to risk of seizures.
METRETON is a fixed-dose combination of metformin and sitagliptin. Use with caution in patients with renal impairment (check e GFR before initiation; contraindicated if e GFR <30 m L/min/1.73 m²). Monitor for lactic acidosis, especially in hypoxic states or hepatic impairment. Discontinue temporarily before iodinated contrast imaging and for surgery. Assess for pancreatitis (discontinue if suspected). Do not use in type 1 diabetes or diabetic ketoacidosis. Dose adjustment of sitagliptin needed if e GFR 30-45 m L/min/1.73 m² (50 mg daily).
Do not drink any alcohol or take products containing alcohol (e.g., mouthwash, cough syrup) while using this medication and for 48 hours after stopping, as it can cause severe nausea, vomiting, headache, and abdominal cramps.,May cause a metallic or bitter taste in the mouth; this is harmless and temporary.,Report any numbness, tingling, or weakness in your arms or legs to your healthcare provider immediately, as this could be a sign of nerve damage.,Take the full course of therapy exactly as prescribed, even if you feel better.,If you have severe liver disease, your dose may need to be adjusted.
Take with meals to reduce gastrointestinal side effects.,Do not drink excessive alcohol while taking this medication.,Monitor for symptoms of lactic acidosis (unusual tiredness, muscle pain, trouble breathing, stomach pain) and pancreatitis (severe stomach pain, nausea, vomiting).,Inform your doctor if you become pregnant or plan to breastfeed.,Report any signs of allergic reaction (rash, hives, swelling of face/lips/throat) immediately.,Maintain adequate fluid intake, especially during illness or in hot weather.,Do not skip meals or drastically reduce carbohydrate intake without consulting your provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METRO I.V. vs METRETON, answered by our medical review team.
METRO I.V. is a Antibiotic (Nitroimidazole) that works by Metronidazole is a nitroimidazole antibiotic that exerts its bactericidal effect by entering bacterial cells and undergoing reduction by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It is selectively toxic to anaerobic bacteria and protozoa.. METRETON is a Antibiotic (Nitroimidazole) that works by Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METRO I.V. and METRETON depend on the specific clinical indication. These are both Antibiotic (Nitroimidazole) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METRO I.V. is: 15-30 mg/kg IV loading dose, then 7.5-15 mg/kg IV every 6 hours. Typical adult dose: 500 mg IV every 6-8 hours.. The standard adult dose of METRETON is: 1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METRO I.V. and METRETON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METRO I.V. is classified as Category C. Pregnancy category B. No evidence of teratogenicity in human studies; crosses placenta. Avoid during first trimester unless benefit outweighs risk; use only if clearly needed.. METRETON is classified as Category C. Pregnancy Category C: Fetal risk cannot be ruled out. First trimester: Increased risk of cleft palate and cardiac malformations due to corticosteroid component (prednisolone). Seco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.